← Therapy pipeline
Investigational · Obesity development

Poterepatide (HDM1005)

HDM1005 · Huadong Medicine

Long-acting injectable GLP-1/GIP dual agonist in China Phase 3 obesity development. U.S. obesity development has not been confirmed.

GLP-1GIP
Obesity stagePhase 3Updated as of November 2026
SponsorHuadong Medicine
TargetsGLP-1 + GIP
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Selected study results

HDM1005 · Phase 2Mean body-weight changeBody weight decreased 13.32% · 22 weeks · Phase 2
Phase 2 · Injection · Conference abstract

Mean body-weight change · 22 weeks

Study focus: Weight management

Phase 2 results reported in an ADA 2026 abstract.

Investigational regimen
13.3%
Placebo / comparator
2.5%

Adults with overweight or obesity in China · 4 mg vs placebo · Trial N=243 · Treatment-policy estimand; conference abstract. Results & methods ↗

Conference abstract and sponsor report; China Phase 3 results are not yet available.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIPTargeted
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

Injection · ChinaInjection
Phase 3China obesity Phase 3 enrollment complete; follow-up/data collection ongoing
Milestone → next

Latest: Huadong reported that China Phase 3 enrollment is complete and data collection is ongoing; pre-NDA communication was expected in Q4 2026.

Next: China pre-NDA consultation and Phase 3 disclosure; U.S./global obesity development remains unconfirmed.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies1 record

Phase 3

HDM1005 obesity Phase 3

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

China obesity Phase 3; sponsor reports enrollment complete with follow-up and data collection ongoing.

Phase 2 studies1 record

Phase 2

HDM1005 obesity Phase 2

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

22-week obesity study; ADA 2026 abstract reported Phase 2 efficacy.